Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Prospektiv, multicenter, ikke-interventionel undersøgelse for at undersøge effektiviteten af ​​REKOVELLE® til ovariestimulering for asiatiske kvinder i virkelige omgivelser (PROFOUND)

29. september 2026 opdateret af: Ferring Pharmaceuticals

Prospektiv, multilande, ikke-interventionel undersøgelse for at undersøge REKOVELLE for ovariestimulering: effektiviteten, sikkerheden og brugsmønstrene for asiatiske kvinder i den virkelige verden

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

1526

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Hiroshima, Japan, 7300035
        • Ferring Investigational Site
      • Hokkaido, Japan, 0600003
        • Ferring Investigational Site
      • Hyōgo, Japan, 6500021
        • Ferring Investigational Site
      • Osaka, Japan, 5300011
        • Ferring Investigational Site
      • Osaka, Japan, 5500015
        • Ferring Investigational Site
      • Saitama, Japan, 3540035
        • Ferring Investigational Site
    • Chiba
      • Chiba, Chiba, Japan, 2610023
        • Ferring Investigational Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 8120013
        • Ferring Investigational Site
      • Kitakyushu, Fukuoka, Japan, 8070825
        • Ferring Investigational Site
    • Gunma
      • Takasaki, Gunma, Japan, 3700841
        • Ferring Investigational Site
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 7320822
        • Ferring Investigational Site
    • Japan
      • Bunkyō City, Japan, Japan, 1130033
        • Ferring Investigational Site
    • Tokyo
      • Tokyo, Tokyo, Japan, 1600023
        • Ferring Investigational Site
      • Busan, Sydkorea, 47245
        • Ferring Investigational Site
      • Seoul, Sydkorea, 02586
        • Maria Fertility Hospital
    • Busan
      • Busan, Busan, Sydkorea, 49241
        • Ferring Investigational Site
    • Daegu
      • Daegu, Daegu, Sydkorea, 41910
        • Ferring Investigational Site
    • Seongnam
      • Seongnam-si, Seongnam, Sydkorea, 13496
        • Ferring Investigational Site
      • Taichung, Taiwan, 406
        • Ferring Investigational Site
      • Taipei, Taiwan, 100225
        • Ferring Investigational Site
      • Taipei, Taiwan, 110
        • Ferring Investigational Site
    • Tainan
      • Tainan, Tainan, Taiwan, 70403
        • Ferring Investigational Site
      • Tainan, Tainan, Taiwan, 71004
        • Ferring Investigational Site
    • Taoyuan
      • Taoyuan, Taoyuan, Taiwan, 333
        • Ferring Investigational Site
      • Bangkok, Thailand, 10700
        • Ferring Investigational Site
    • Muang
      • Phitsanulok, Muang, Thailand, 65000
        • Naresuan University Hospital
    • Ratchathewi
      • Bangkok, Ratchathewi, Thailand, 10400
        • Ramathibodi Hospital
    • Hanoi
      • Hanoi, Hanoi, Vietnam, 100000
        • Ferring Investigational Site
    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
        • Ferring Investigational Site
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • Ferring Investigational Site
    • Huế
      • Huế, Huế, Vietnam, 49000
        • Ferring Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

N/A

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

Beskrivelse

Inclusion Criteria:

  • Females aged 20 years or older at enrollment
  • Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
  • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
  • Participating in an interventional clinical trial in which any medication treatment is mandated
  • Women with a contraindication for prescription of REKOVELLE treatment
  • Oocyte donors
  • Undergoing ovarian stimulation for fertility preservation

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
REKOVELLE

Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.

Individualised dosing regiment of REKOVELLE in routine clinical practice.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative live birth rate
Tidsramme: Up to 12 months

Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

Up to 12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The Luteinising hormone (LH) surge suppression protocol
Tidsramme: Up to 22 days

Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.

Up to 22 days
Daily Dosage
Tidsramme: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.

Up to 22 days
Stimulation Duration
Tidsramme: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.

Up to 22 days
Total Dosage
Tidsramme: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.

Up to 22 days
Trigger Protocol
Tidsramme: Up to 22 days

Treatment pattern will be measured by analysing the trigger protocol.

Up to 22 days
Luteal phase support protocol
Tidsramme: Up to 22 days

Treatment pattern will be measured by analysing the luteal phase support protocol.

Up to 22 days
Number of oocytes retrieved
Tidsramme: Up to 22 days

Number of oocytes retrieved at oocyte retrieval

Up to 22 days
Number of Metaphase II (MII) oocytes
Tidsramme: Up to 22 days

Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))

Up to 22 days
Number of embryos
Tidsramme: Day 3 after oocyte retrieval

Number of embryos on Day 3 after oocyte retrieved

Day 3 after oocyte retrieval
Number of Blastocysts
Tidsramme: Day 5 after oocyte retrieval

Number of Blastocysts on Day 5 after oocyte retrieved

Day 5 after oocyte retrieval
Number of embryos transferred
Tidsramme: Up to 28 days

Embryos transferred in fresh and/or frozen transfer cycles

Up to 28 days
Number of blastocysts transferred
Tidsramme: Up to 28 days

Blastocysts transferred in fresh and/or frozen transfer cycles

Up to 28 days
Implantation rate
Tidsramme: Up to 28 days

Number of gestational sacs, embryos or blastocysts transferred

Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
Tidsramme: 11 to 15 days after transfer

Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer

11 to 15 days after transfer
Clinical Pregnancy rate
Tidsramme: 4 to 5 weeks after transfer

Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)

4 to 5 weeks after transfer
Vital Pregnancy
Tidsramme: 4 to 5 weeks after transfer

Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)

4 to 5 weeks after transfer
Ongoing pregnancy rate
Tidsramme: 9 to 11 weeks after transfer

Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)

9 to 11 weeks after transfer
Time to pregnancy
Tidsramme: 4 to 5 weeks after transfer

Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy

4 to 5 weeks after transfer
Live birth rate
Tidsramme: More than 20 weeks after transfer

Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

More than 20 weeks after transfer
Multiple pregnancy rate
Tidsramme: 4 to 5 weeks after transfer

More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer

4 to 5 weeks after transfer
Spontaneous abortion rate
Tidsramme: Up to 10-11 weeks after transfer

Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound

Up to 10-11 weeks after transfer
Ectopic pregnancy rate
Tidsramme: Up to 10-11 weeks after transfer

Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

Up to 10-11 weeks after transfer
Estradiol Hormone levels
Tidsramme: Up to 20 days

Estradiol hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Progesterone Hormone levels
Tidsramme: Up to 20 days

Progesterone hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
Tidsramme: Up to 28 days

Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)

Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
Tidsramme: Up to 28 days

Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).

Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Tidsramme: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Frequency and severity of ADRs and SAEs as defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Tidsramme: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.

Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Tidsramme: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Number of subjects with mild / moderate / severe OHSS, defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Global Clinical Compliance, Ferring Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. august 2024

Primær færdiggørelse (Anslået)

1. maj 2027

Studieafslutning (Anslået)

1. august 2027

Datoer for studieregistrering

Først indsendt

6. august 2024

Først indsendt, der opfyldte QC-kriterier

16. august 2024

Først opslået (Faktiske)

20. august 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 000430

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .